Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We At?

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2025 Jan 8

PMID 39768911

Authors

Miodrag Janic

Sabina Skrgat

Matevz Harlander

Mojca Lunder

Andrej Janez

Anca Pantea Stoian

Mohamed El-Tanani

Viviana Maggio

Manfredi Rizzo

Affiliations

Soon will be listed here.

Abstract

Chronic respiratory disorders are the third leading cause of mortality globally. Consequently, there is a continuous pursuit of effective therapies beyond those currently available. The therapeutic potential of the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide/GLP-1 (GIP/GLP-1) receptor agonists extends beyond the regulation of glycemia, including glucometabolic, cardiovascular, and renal effects, rendering them viable candidates, due to their mechanisms of action, for the possible treatment of respiratory disorders. This manuscript aims to provide a comprehensive evaluation of the evidence on potential direct (cellular) and indirect (metabolic) actions of GLP-1 and GIP/GLP-1 receptor agonists within the pulmonary systems. In addition, it examines their efficacy in addressing prevalent respiratory disorders, specifically chronic obstructive pulmonary disease (COPD), asthma, pneumonia, obstructive sleep apnea, pulmonary hypertension, lung cancer, and lung transplantation. Finally, the manuscript seeks to identify potential avenues for further focused research in this field.

References

Jiang W, Li W, Cheng J, Li W, Cheng F . Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. Sleep Breath. 2022; 27(5):1687-1694. PMC: 10539428. DOI: 10.1007/s11325-022-02768-y. View

Blackman A, Foster G, Zammit G, Rosenberg R, Aronne L, Wadden T . Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016; 40(8):1310-9. PMC: 4973216. DOI: 10.1038/ijo.2016.52. View

Le K, Le K, Foo F . The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review. Pharmacy (Basel). 2024; 12(1). PMC: 10801460. DOI: 10.3390/pharmacy12010011. View

Liu C, Zhang Q, Zhou H, Jin L, Liu C, Yang M . GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome/PFKFB3-driven glycolysis interaction and histone lactylation. J Transl Med. 2024; 22(1):954. PMC: 11492558. DOI: 10.1186/s12967-024-05753-z. View

Mendivil C, Koziel H, Brain J . Metabolic hormones, apolipoproteins, adipokines, and cytokines in the alveolar lining fluid of healthy adults: compartmentalization and physiological correlates. PLoS One. 2015; 10(4):e0123344. PMC: 4388476. DOI: 10.1371/journal.pone.0123344. View

Kaplan A, Kim J . Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence. Pulm Ther. 2022; 8(4):343-358. PMC: 9727043. DOI: 10.1007/s41030-022-00203-x. View

Pradhan R, Lu S, Yin H, Yu O, Ernst P, Suissa S . Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. BMJ. 2022; 379:e071380. PMC: 9623550. DOI: 10.1136/bmj-2022-071380. View

Zhu Z, Zeng Q, Liu Q, Wen J, Chen G . Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2022; 5(12):e2244652. PMC: 9856231. DOI: 10.1001/jamanetworkopen.2022.44652. View

Cazzola M, Matera M, Calzetta L, Lauro D, Rogliani P . Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database. J Asthma. 2024; 61(12):1638-1645. DOI: 10.1080/02770903.2024.2372600. View

10.

Choi W, Choe S, Lin J, Borchers M, Kosmider B, Vassallo R . Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPARγ-FOXA2-phosphatase signaling. Mucosal Immunol. 2020; 13(4):637-651. PMC: 7664156. DOI: 10.1038/s41385-020-0262-1. View

11.

Lee B, Man K, Wong E, Tan T, Sheikh A, Bloom C . Antidiabetic Medication and Asthma Attacks. JAMA Intern Med. 2024; 185(1):16-25. PMC: 11574725. DOI: 10.1001/jamainternmed.2024.5982. View

12.

Wang A, Tang H, Zhang N, Feng X . Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials. Diabetes Res Clin Pract. 2021; 183:109080. DOI: 10.1016/j.diabres.2021.109080. View

13.

Hua J, Lin H, Wang X, Qian Z, Vaughn M, Tabet M . Associations of glycosylated hemoglobin, pre-diabetes, and type 2 diabetes with incident lung cancer: A large prospective cohort study. Diabetes Metab Syndr. 2024; 18(2):102968. DOI: 10.1016/j.dsx.2024.102968. View

14.

Mafort T, Rufino R, Henrique Costa C, Lopes A . Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function. Multidiscip Respir Med. 2016; 11:28. PMC: 4940831. DOI: 10.1186/s40248-016-0066-z. View

15.

Zhang M, Lin C, Cai X, Jiao R, Bai S, Li Z . The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis. Biomed Environ Sci. 2024; 37(6):607-616. DOI: 10.3967/bes2024.067. View

16.

Tabernacki T, Wang L, Kaelber D, Xu R, Berger N . Non-Insulin Antidiabetic Agents and Lung Cancer Risk in Drug-Naive Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study. Cancers (Basel). 2024; 16(13). PMC: 11240387. DOI: 10.3390/cancers16132377. View

17.

de Mesquita Y, Pera Calvi I, Marques I, Cruz S, Padrao E, Carvalho P . Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. Int J Obes (Lond). 2023; 47(10):883-892. DOI: 10.1038/s41366-023-01337-x. View

18.

Hendriks L, Remon J, Faivre-Finn C, Garassino M, Heymach J, Kerr K . Non-small-cell lung cancer. Nat Rev Dis Primers. 2024; 10(1):71. DOI: 10.1038/s41572-024-00551-9. View

19.

Ehrlich S, Quesenberry Jr C, Van Den Eeden S, Shan J, Ferrara A . Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2009; 33(1):55-60. PMC: 2797986. DOI: 10.2337/dc09-0880. View

20.

Sprung V, Kemp G, Wilding J, Adams V, Murphy K, Burgess M . Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive.... BMJ Open. 2020; 10(7):e038856. PMC: 7380950. DOI: 10.1136/bmjopen-2020-038856. View